Загрузка...
A Phase II Study of Pazopanib in Patients with Malignant Pleural Mesothelioma: NCCTG N0623 (Alliance)
PURPOSE: Preclinical and clinical data have shown promise in using antiangiogenic agents to treat malignant pleural mesothelioma (MPM). We conducted this phase II study to evaluate the efficacy and toxicity of single‐agent pazopanib in patients with MPM. MATERIALS AND METHODS: Patients with MPM who...
Сохранить в:
| Опубликовано в: : | Oncologist |
|---|---|
| Главные авторы: | , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
John Wiley & Sons, Inc.
2019
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7288653/ https://ncbi.nlm.nih.gov/pubmed/31872928 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2019-0574 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|